COPD study for Brazilian patients
Part of Lungs & breathing clinical trials.
This study looks at the health of Brazilian adults with COPD. It aims to understand how the condition affects people and may help improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have a confirmed COPD diagnosis based on recent guidelines or symptoms
- You may qualify if you’ve had a COPD flare-up that required a hospital stay or medication change
- You may also qualify if your lung function is below a certain level
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with severe or very severe COPD to learn more about their health over time. You may qualify if your COPD causes many symptoms or frequent flare-ups.
This study looks at how well a triple inhaler (BDP/FF/GB) works for people with severe COPD in Brazil. It may help those who have had at least one flare-up in the past year.
This trial looks at how long-term health conditions like heart disease, diabetes, or high blood pressure might affect breathing problems. The goal is to better understand and help people with both issues.
This study looks at different forms of COPD to find better ways to treat them. It may help you understand your own condition and receive more personalized care.
This study looks at how to better manage chronic diseases like lung problems along with other ongoing conditions. It may test a simple breathing test at your primary health center to find lung issues early.
This study follows people with COPD (chronic lung disease) over many years to better understand the condition. It may help doctors learn what factors predict worsening over time.
Hear when a new COPD (Chronic Obstructive Pulmonary Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.